Evidence map›Paper›PMID 31275589›Full record

ArticleBMJ open gastroenterology2019

Methylated

Megan P Hitchins, Ingrid P Vogelaar, Kevin Brennan, Sigurdis Haraldsdottir, Nianmin Zhou, Brock Martin, Rocio Alvarez, Xiaopu Yuan, Sungjin Kim, Maha Guindi and 12 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06163365 (Inherited Cancer Early Diagnosis), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06163365 unknown statusnot on this mapstarted 2022, after this paper: background citation

Inherited Cancer Early Diagnosis (ICED) Study Liquid Biopsy Screening for Early Diagnosis of Cancers in Patients With Cancer-predisposition Syndromes

Typeobservational_patient_registrySponsorRoyal Marsden NHS Foundation TrustRan2022 to 2025Enrolled100ConditionsLi Fraumeni Syndrome, Lynch Syndrome, Hereditary Diffuse Gastric Cancer, Cowden Syndrome
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Methylated Septin9 (mCancer research communications · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Megan P HitchinsBiomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID 0000-0002-3603-2309
Ingrid P VogelaarMedicine, Stanford University, Stanford, California, USA.
Kevin BrennanMedicine, Stanford University, Stanford, California, USA.
Sigurdis HaraldsdottirMedicine, Stanford University, Stanford, California, USA.
Nianmin ZhouMedicine, Stanford University, Stanford, California, USA.
Brock MartinMedicine, Stanford University, Stanford, California, USA.
Rocio AlvarezBiomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Xiaopu YuanDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Sungjin KimMedicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Maha GuindiDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Andrew E HendifarSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, USA.
Matthew F KaladyDepartments of Stem Cell and Regenerative Medicine and Colorectal Surgery, Sanford R Weiss MD Center for Hereditary Colorectal Neoplasia, Digestive Disease and Surgery Institute, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.
Jennifer DeVecchioDepartment of Stem Cell and Regenerative Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.
James M ChurchDepartments of Stem Cell and Regenerative Medicine and Colorectal Surgery, Sanford R Weiss MD Center for Hereditary Colorectal Neoplasia, Digestive Disease and Surgery Institute, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.
Albert de la ChapelleDepartment of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.
Heather HampelDepartment of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.
Rachel PearlmanDepartment of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.
Maria ChristensenHereditary Cancer Center, Creighton University, Omaha, Nebraska, USA.
Carrie SnyderHereditary Cancer Center, Creighton University, Omaha, Nebraska, USA.
Stephen J LanspaHereditary Cancer Center, Creighton University, Omaha, Nebraska, USA.
Robert W Haile *Department of Medicine, Research Center for Health Equity, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Henry T Lynch *Hereditary Cancer Center, Creighton University, Omaha, Nebraska, USA.
Cedars-Sinai Medical Center · USStanford University · USCreighton University · USCleveland Clinic Lerner College of Medicine · USThe Ohio State University · US

Funding

Cedars-Sinai Biobank and Translational Research Core Facility (CS-BRCF)G20RR030860 · NCRR · CEDARS-SINAI MEDICAL CENTER · PI MELMED, SHLOMO · 2010 to 2010
$9.6M
NCRR NIH HHS G20 RR030860
6 · The paper itself

Abstract

objectiveThe plasma-based methylated

designFirstly, SEPT9 methylation was measured in LS-associated CRC, advanced adenoma, and subject-matched normal colorectal mucosa tissues by pyrosequencing. Secondly, to detect mSEPT9 as circulating tumor DNA, the plasma-based mSEPT9 test was retrospectively evaluated in LS subjects using the Epi proColon 2.0 CE assay adapted for 1mL plasma using the "1/1 algorithm". LS case groups included 20 peri-surgical cases with acolonoscopy-based diagnosis of CRC (stages I-IV), 13 post-surgical metastatic CRC, and 17 pre-diagnosis cases. The control group comprised 31 cancer-free LS subjects.

resultsDifferential hypermethylation was found in 97.3% (36/37) of primary CRC and 90.0% (18/20) of advanced adenomas, showing LS-associated neoplasia frequently produce the mSEPT9 biomarker. Sensitivity of plasma mSEPT9 to detect CRC was 70.0% (95% CI, 48%-88%)in cases with a colonoscopy-based CRC diagnosis and 92.3% (95% CI, 64%-100%) inpost-surgical metastatic cases. In pre-diagnosis cases, plasma mSEPT9 was detected within two months prior to colonoscopy-based CRC diagnosis in 3/5 cases. Specificity in controls was 100% (95% CI 89%-100%).

conclusionThese preliminary findings suggest mSEPT9 may demonstrate similar diagnostic performance characteristics in LS as in the average-risk population, warranting a well-powered prospective case-control study.

Indexed as

circulating tumor dnacolorectal cancerlynch syndromeplasmaSEPTIN9

Identifiers

PMID31275589
PMCPMC6577308
OpenAlexW2947274563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.